Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Trial details
- Registry ID
- NCT03946449
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Fazirsiran Injection; TAK-999
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)NCT03946449 | Arrowhead Pharmaceuticals | Phase 2 | Completed | 2022-04-28Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |